Full-Time

Scientist II/Senior Scientist

In vivo Pharmacology, Oncology

Posted on 9/13/2025

Hexagon Bio

Hexagon Bio

51-200 employees

Genomics-driven discovery of small-molecule inhibitors

Compensation Overview

$140k - $170k/yr

+ Bonus + Equity

Menlo Park, CA, USA

In Person

Category
Lab & Research (5)
, , , ,
Requirements
  • PhD in Cancer Biology, Immunology, Pharmacology, or related discipline with 3-5 years of industrial experience.
  • Extensive knowledge of tumor biology is required.
  • Must have hands-on experience with in vivo rodent models and ex vivo tissue analysis.
  • Strong knowledge and expertise with multicolor flow cytometry is required.
  • Experience with tissue immunohistochemistry is preferred.
  • Experience with coordinating CROs and/or external collaborators is desirable.
  • Familiarity with ADCs is a plus.
  • A collaborative, team-oriented approach, able to take on problems in a goal-focused fashion.
  • Effective communication and ability to coordinate tasks across multiple projects as part of a multidisciplinary research team.
  • Self-motivation, initiative and boldness to dive into a fast-paced new startup.
Responsibilities
  • Design and manage in vivo experiments at external vivarium facilities to evaluate the efficacy of antibody-drug conjugates (ADCs).
  • Drive the selection, development and characterization of preclinical tumor models, ensuring reproducibility and appropriate use of standard-of-care controls.
  • Develop and execute biomarker assays on tissues using multicolor flow cytometry and immunohistochemistry to support ADC mechanism of action.
  • Design and perform in vitro pharmacology experiments to complement in vivo findings.
  • Analyze and synthetize complex experimental data using appropriate statistical methods, interpret results to guide decision-making processes.
  • Collaborate with a diverse team of biologists, chemists and CROs to answer scientific questions and deliver quality and timely findings in support of candidate advancement.
  • Effectively communicate findings and interpretation of results to multi-disciplinary teams.
  • Stay abreast of preclinical models applied to ADCs.
  • Comply with company health and safety policies and general laboratory practices.

Hexagon Bio uses synthetic biology and data science to discover and develop new medicines by analyzing genomic data from thousands of species to find small molecules that inhibit disease-related proteins. Its proprietary algorithm searches genomes to identify lead compounds and its platform can quickly turn those molecules into candidates suitable for clinical development. The company blends computational biology, chemistry, and synthetic biology to move from genome data to drug candidates faster, and it leverages inexpensive sequencing to access diverse genetic information while producing leads in-house. Its goal is to build a steady pipeline of drug candidates and license them to larger pharmaceutical companies to advance through clinical trials and commercialization.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$183.6M

Headquarters

Menlo Park, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $77.3M Series B in 2024 funds preclinical ADC programs expansion.
  • Exponential metagenomic data growth enables discovery of diverse therapeutics first.
  • Licensing model monetizes platform via pharma partnerships across indications.

What critics are saying

  • Corteva JV diverts R&D from oncology to agriculture in 2024.
  • Synaffix and ADC Therapeutics advance superior payloads into clinic by 2025.
  • No Phase 1 candidates by mid-2026 triggers investor withdrawal.

What makes Hexagon Bio unique

  • Proprietary platform mines fungal genomes for novel ADC payloads overcoming resistance.
  • Builds 10x larger proprietary metagenomic database than public ones.
  • Combines data science, synthetic biology, and automation for rapid compound production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-5%
InvestorsObserver
Feb 13th, 2023
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules

Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules

Vator
Sep 23rd, 2021
The Column Group LLC invests into Hexagon Bio in $61M

Hexagon Bio has raised $61 million in funding led by Nextech, with participation from SoftBank, Casdin Capital and earlier investors The Column Group, 8VC and Two Sigma Ventures.

Business Wire
Sep 22nd, 2021
Hexagon Bio Raises $61 Million to Advance Novel Small-Molecule Medicines Mined from Microbial Genomes

MENLO PARK, Calif.--(BUSINESS WIRE)--Hexagon Bio, a biopharmaceutical company mining microbial genomes to discover new medicines, has raised $61M to advance preclinical programs.

Finsmes
Sep 15th, 2020
Hexagon Bio Closes $47M Series A Financing

Hexagon Bio, Inc., a Menlo Park, Calif.-based biotechnology company turning nature's genomes into medicines, raised $47m in Series A financing

INACTIVE